The rapid growth of knowledge about human T-lymphotropic virus type III/limphadenopathy -associated virus (HTLV-III/LAV) has resulted in an increasing need for a system of classifying patients within this spectrum of clinical and laboratory findings attributable to HTLV-III/LAV infection.